Pharmaceuticals

Pulmonary Or Respiratory Drug Delivery Market Size Forecast: Revenue and CAGR by 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Pulmonary Or Respiratory Drug Delivery Industry Expected To Reach By 2029, Starting From 2025 Levels?

The pulmonary or respiratory drug delivery market has experienced substantial expansion in recent years. Its valuation is anticipated to climb from $69.83 billion in 2024 to $75.67 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.4%. This historical growth stems from factors including the increasing prevalence of asthma, enhanced adoption of advanced inhalation devices, a worldwide increase in healthcare spending, elevated awareness regarding respiratory conditions, and a growing occurrence of allergic conditions.

Significant expansion is anticipated for the pulmonary or respiratory drug delivery market in the coming years. This market is projected to reach $105.32 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 8.6%. This growth during the projected period stems from increased demand for personalized medicine, a higher incidence of chronic respiratory conditions, a stronger focus on telemedicine, greater investments in healthcare infrastructure, and the expansion of e-commerce for pharmaceutical goods. Key trends expected within this period involve innovations in particle engineering, the creation of sophisticated nebulizers, the emergence of liposomal formulations, progress in computational fluid dynamics, and the introduction of smart inhalers.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp

What Are The Main Drivers Boosting The Pulmonary Or Respiratory Drug Delivery Industry’s Expansion?

The rising incidence of pneumonia is anticipated to stimulate future expansion in the pulmonary or respiratory drug delivery market. Pneumonia, a lung infection, leads to inflammation of the air sacs, potentially causing them to fill with fluid or pus, resulting in symptoms such as coughing, fever, and impaired breathing. The growing occurrence of pneumonia is linked to factors including aging populations, compromised immune systems, respiratory infections, atmospheric pollution, smoking, and the emergence of antibiotic-resistant bacteria. Pulmonary or respiratory drug delivery assists individuals suffering from pneumonia by administering medications, like antibiotics, bronchodilators, or anti-inflammatory agents, straight to the lungs. This facilitates more rapid and potent treatment, easing symptoms, diminishing inflammation, eradicating infections, and enhancing lung function, thereby improving recuperation and averting complications. For example, data from November 2023, provided by the Centre for Tropical Medicine and Global Health, a UK-based leader in healthcare research, indicated a substantial increase in pneumonia cases in Kenya, reaching 793,864 during 2022/2023. Consequently, the expanding incidence of pneumonia is a key driver for the pulmonary or respiratory drug delivery market.

What Are The Primary Types Of Segments Analyzed In The Pulmonary Or Respiratory Drug Delivery Market?

The pulmonary or respiratory drug delivery market covered in this report is segmented –

1) By Product: Formulation Type, Device Type

2) By Canister Type: Plain Canister, Coated Canister

3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications

4) By End-User: Hospitals, Clinics, Home Care Settings

Subsegments:

1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays

2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices

What Trends Are Redefining The Pulmonary Or Respiratory Drug Delivery Market Dynamics?

Major companies in the pulmonary or respiratory drug delivery market are increasingly focusing on technological advancements, such as complex drug delivery systems, to improve treatment efficacy and patient compliance. These advanced technologies enhance the targeted delivery and controlled release of therapeutic agents, leading to better drug efficacy and patient outcomes. For instance, in July 2023, Viatris Inc., a US-based healthcare company manufacturing generic and branded medicines, along with Kindeva Drug Delivery L.P., a US-based company providing drug delivery services, introduced Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This inhalation aerosol, approved by the Food and Drug Administration, a US-based government agency, is the first generic version of AstraZeneca’s Symbicort. It is a metered-dose inhaler combining budesonide and formoterol, used for treating asthma and chronic obstructive pulmonary disease, and is available in two strengths: 80 micrograms and 160 micrograms, each with 4.5 micrograms of formoterol.

Which Industry Leaders Are Driving Innovation Across The Pulmonary Or Respiratory Drug Delivery Market?

Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report

What Regional Growth Trends Are Shaping The Pulmonary Or Respiratory Drug Delivery Market Outlook?

North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Pulmonary Or Respiratory Drug Delivery Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp

Browse Through More Reports Similar to the Global Pulmonary Or Respiratory Drug Delivery Market 2025, By The Business Research Company

Pulmonary Arterial Hypertension Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

Chronic Obstructive Pulmonary Disease Copd Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Idiopathic Pulmonary Fibrosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795